

NYSE LIFFE LISTS EQUITY OPTIONS ON GALAPAGOS

Released : 30 April 2013

April 30, 2013

Brussels and Mechelen, Belgium, 30 April 2013 – Today NYSE Liffe, the Europe-based derivatives business of NYSE Euronext (NYSE), added options on the shares of Galapagos (Euronext: GLPG), a clinical stage biotech company focused on developing novel medicines, to its highly successful range of equity option classes. The options are available on the Brussels derivatives market of NYSE Liffe under the ticker GLS.

Vincent Van Dessel, CEO of NYSE Euronext Brussels commented: “ *We are pleased to announce the listing of options on Galapagos, a successful Belgian company and a great example of our leading role in the biotech industry niche. This listing will further enhance the visibility of the company.* ”

Ade Cordell, Executive Director, Head of Equity Derivatives added: “ *We are delighted with the listing of this new option class on our Brussels market. With the addition of the Galapagos option class to our existing central order book contracts, we are offering our market participants a highly diversified set of liquid derivatives for their investment needs.* ”

Onno van de Stolpe, CEO of Galapagos, commented: “ *Listing of ordinary shares on NYSE Euronext has played an important role in the growth of Galapagos since the IPO in 2005. The listing of options on the shares of our company marks a further step in the company's development. We believe that this may offer shareholders an alternative financial instrument on the NYSE Liffe market, enhance the liquidity of our share, and increase the visibility of Galapagos in the financial markets.* ”

These American-style options will expire on the third Friday of the expiry month and will have initial lifetimes of one to twelve months. Options on Galapagos are introduced under trading symbol GLS.

Each option represents 100 shares in Galapagos and will be centrally cleared via LCH.Clearnet SA. Liquidity in the options will be supported by All Options International B.V.. NYSE Liffe lists stock options (also known as individual equity options) on more than 200 leading European companies via the Amsterdam, Brussels, London and Paris central order books.

The introduction of the new option class on Galapagos is the second one on a Belgian biotech company. Galapagos is specialized in novel modes-of-action medicines, with a large pipeline of four clinical, seven pre-clinical, and 30 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications. The Galapagos Group, including fee-for-service companies BioFocus, Argenta and Fidelta, has around 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium.

To mark today's special occasion, Onno van de Stolpe, CEO of Galapagos, rang the opening bell which denotes the opening of NYSE Euronext's European market, together with Vincent Van Dessel, CEO of NYSE Euronext Brussels.

Information

NYSE Euronext

Jean-Yves Daxhelet

Tel.: +32 (0)2 213 13 03

Email: jean-yves.daxhelet@interelgroup.com

Galapagos

Elizabeth Goodwin, Director Investor Relations

Tel.: +31 6 2291 6240

E-mail: ir@glpg.com

About NYSE Euronext

NYSE Euronext (NYSE) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets - the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca - represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more information, please visit: <http://www.nyx.com>.

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action, with a large pipeline of four clinical, seven pre-clinical, and 30 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications.

GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, about to enter Phase 2b studies. AbbVie and Galapagos signed a worldwide license agreement whereby AbbVie will be responsible for further development and commercialization after Phase 2b. Galapagos has another selective JAK1 inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012). **GLPG0187** is a novel integrin receptor antagonist currently in a Phase 1b patient study in metastasis. **GLPG0974** is the first inhibitor of FFA2 to be evaluated clinically for the treatment of IBD; this program is currently in a Proof of Concept Phase 2 study, with results expected early 2014.

The Galapagos Group, including fee-for-service companies **BioFocus**, **Argenta** and **Fidelta**, has around 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium. Further information at: www.glp.com

Disclaimer

None of the information contained in this press release constitutes an offer, solicitation or recommendation to acquire or dispose of any security or investment or to engage in any other transaction or to provide legal, tax, accounting or investment advice or services regarding the suitability or profitability of any security or investment. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by NYSE Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. NYSE Euronext offers no view on whether investments are appropriate for you and recommends you obtain independent advice in respect of such investments. Persons wishing to trade products available on NYSE Euronext markets or wishing to offer such products to third parties (whether by way of admission to listing and/or trading of products, or otherwise) are advised, before doing so, to check their legal and regulatory position in the relevant territory and to understand the related risks. NYSE Euronext does not make any recommendations regarding the merit of any company, security or other financial product or investment identified in this press release. Similarly, NYSE Euronext does not make any recommendation regarding the purchase or sale of any company, security, financial product or investment, endorsed or sponsored by any company identified in this press release. This press release is not intended to be, and shall not constitute in any way a binding or legal agreement, or impose any legal obligation or duty on NYSE Euronext or any of its affiliates. This press release speaks only as of this date. NYSE Euronext disclaims any duty to update the information herein.

NYSE Euronext refers to NYSE Euronext and its affiliates and references to NYSE Euronext in this publication include each and any such company as the context dictates. NYSE Euronext, New York Stock Exchange, NYSE MKT, NYSE Alternext, NYSE Arca and NYSE Liffe are registered marks of NYSE Euronext. © 2013, NYSE Euronext – All rights reserved.